To assess the clinical performance and safety of HEMOPATCH Sealing Hemostat in a post-marketing setting in cardiovascular, thoracic, urologic, neurological, and other general surgical procedures.

Inclusion Criteria:

• Male or female patients of any age

• Patients who had undergone open or minimal invasive surgical (MIS) procedures requiring the use of a patch to achieve dura repair, hemostasis, or control of leakage of air or other body fluid when pressure, ligature or other conventional procedures had been ineffective or impractical and where use of hemopatch was deemed appropriate by the surgeon according to its IFU in the following organ systems:

  1. Hepato-biliary (liver, pancreas, gallbladder)
  2. General surgery (in thyroid and other regions)
  3. Cardiovascular (heart and vessels)
  4. thoracic (lung and mediastinum)
  5. Urological (kidney, prostate, and bladder
  6. Neurological (dura mater, brain and spinal cord)

• Provision of written informed consent/assent, as applicable, up to 72 hours after the date of surgery

Exclusion Criteria:

• Patients with known hypersensitivity to bovine proteins or brilliant blue
• Patients who had intraoperative pulsatile or severe bleeding at the target application site (TAS)
• Patients who had an active infection at the TAS

Patient who had undergone a general, cardiovascular, thoracic, urological, or neurological surgery during which the use of a patch was required to repair the dura or to achieve hemostasis, control leakage of air or other body fluid because pressure, ligature or conventional procedures were ineffective or impractical and during which Hemopatch was used according to Instructions for use.